Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xilio Therapeutics, Inc. (XLO) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Xilio Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1840233.
Total stock buying since 2021: $35,088,401.
Total stock sales since 2021: $4,240.
Total stock option exercises since 2021: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 106,289 | $72,771 | 0 | $0 | 0 | $0 |
| 2024 | 2,245,228 | $2,199,167 | 5,235 | $4,240 | 0 | $0 |
| 2021 | 2,067,469 | $32,816,463 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 106,289 | $72,771 | 0 | $0 | 0 | $0 |
| 2024-12 | 1,759,978 | $1,830,377 | 0 | $0 | 0 | $0 |
| 2024-04 | 485,250 | $368,790 | 0 | $0 | 0 | $0 |
| 2024-02 | 0 | $0 | 1,000 | $640 | 0 | $0 |
| 2024-01 | 0 | $0 | 4,235 | $3,600 | 0 | $0 |
| 2021-12 | 42,469 | $416,463 | 0 | $0 | 0 | $0 |
| 2021-10 | 2,025,000 | $32,400,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-17 | Shannon James Samuel | Buy | 25,000 | .69 | 17,225 |
| 2025-06-16 | Russo Rene (PRESIDENT AND CEO) | Buy | 36,289 | .68 | 24,676 |
| 2025-06-16 | Shannon James Samuel | Buy | 45,000 | .69 | 30,870 |
| 2024-12-18 | Gilead Sciences, Inc. (10% Owner) | Buy | 1,759,978 | 1.04 | 1,830,377 |
| 2024-04-02 | Gilead Sciences, Inc. (10% Owner) | Buy | 485,250 | .76 | 368,790 |
| 2024-02-08 | Atlas Venture Associates Opportunity I, Llc (10% Owner) | Sale | 1,000 | .64 | 640 |
| 2024-01-12 | Atlas Venture Associates Opportunity I, Llc (10% Owner) | Sale | 2,100 | .83 | 1,743 |
| 2024-01-11 | Atlas Venture Associates Opportunity I, Llc (10% Owner) | Sale | 2,135 | .87 | 1,857 |
| 2021-12-10 | Bcip Life Sciences Associates, Lp (10% Owner) | Buy | 25,000 | 9.90 | 247,500 |
| 2021-12-09 | Bcip Life Sciences Associates, Lp (10% Owner) | Buy | 4,011 | 9.84 | 39,484 |
| 2021-12-08 | Bcip Life Sciences Associates, Lp (10% Owner) | Buy | 13,458 | 9.62 | 129,479 |
| 2021-10-26 | Four Pines Master Fund Lp | Buy | 500,000 | 16.00 | 8,000,000 |
| 2021-10-26 | Deerfield Mgmt V, L.p. | Buy | 775,000 | 16.00 | 12,400,000 |
| 2021-10-26 | Atlas Venture Opportunity Fund I, L.p. | Buy | 187,500 | 16.00 | 3,000,000 |
| 2021-10-26 | Rivervest Venture Fund Iv, L.p. (10% Owner) | Buy | 250,000 | 16.00 | 4,000,000 |
| 2021-10-26 | Bay City Capital Llc | Buy | 312,500 | 16.00 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of XLO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Xilio Therapeutics, Inc. (symbol XLO, CIK number 1840233) see the Securities and Exchange Commission (SEC) website.